Clinical Trial Update: Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer [Phase 2]

View source ↗

Summary

This is a completed Phase 2 clinical trial evaluating sunitinib plus docetaxel as second-line treatment for advanced gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Sutent (sunitinib)
• Taxotere (docetaxel)

Snippet

Sponsor: Samsung Medical Center | Conditions: Advanced Gastric Cancer | Phase 2 | Status: COMPLETED